Compare Alcon AG (ALC) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Freshworks Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Freshworks Inc trades at $10.27 (market cap $2.87B). The key difference: Alcon AG is far larger — about 11.4× Freshworks Inc's market cap, and Alcon AG pays a 0.54% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| ALC | FRSH | |
|---|---|---|
Market Cap | $32.69B | $2.87B |
Sector | Health | Technology |
52-Week High | $92.22 | $15.36 |
52-Week Low | $62.02 | $6.88 |
Enterprise Value | $36.28B | $2.13B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Freshworks (FRSH) trades at $10.38, up 0.39% with a bullish technical signal. The company shows strong revenue growth from $498M in 2022 to $839M in 2025, achieving profitability with a net margin of 20.69%. Recent news highlights AI-driven service platform adoption, including Vanquis selecting Freshservice. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook is positive due to accelerating revenue growth and expanding margins, though high EV/EBITDA of 48.15 suggests premium valuation. Risks include competitive pressures in SaaS and execution challenges in sustaining growth. Upside potential exists if the company maintains its earnings beat trend and capitalizes on AI integration demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
